TherioPharm: what changed
What changed
TherioPharm
filed annual accounts (NBB)
Net result for the year
-€4,423
2024 · -€721-€3,702
Equity
-€113
2024 · €4,310-€4,423
Cash
€4,763
2024 · €4,310+€453
Balance sheet total
€9,763
2024 · €4,310+€5,453
Largest movements
Assets
- Intangible fixed assets +€5,000
new in 2025: €5,000
- Cash +€453
up €453 (+10.5%), from €4,310 to €4,763
mainly Other debts (+€9,876)
Equity and liabilities
- Other debts +€9,876
new in 2025: €9,876
- Profit (loss) carried forward -€4,423
down €4,423 (-28.2%), from -€15,690 to -€20,113
Income statement
- Gross operating margin -€3,720
down €3,720 (-679%), from -€548 to -€4,268
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
-€721
Gross operating margin
-€3,720
Financial charges
+€19
Result 2025
-€4,423
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
+€5,453
Investment
-€5,000
Financing
€0
Cash 2024
€4,310
From operations (derived)
+€5,453
Net result for the year
-€4,423
Other debts
+€9,876
Investment (derived)
-€5,000
Investment in fixed assets (net)
-€5,000
Cash 2025
€4,763
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €4,310 | €9,763 | +€5,453 | +127% |
| Fixed assets | 21/28 | - | €5,000 | +€5,000 | |
| Intangible fixed assets | 21 | - | €5,000 | +€5,000 | |
| Current assets | 29/58 | €4,310 | €4,763 | +€453 | +10.5% |
| Cash at bank and in hand | 54/58 | €4,310 | €4,763 | +€453 | +10.5% |
| Total equity and liabilities | 10/49 | €4,310 | €9,763 | +€5,453 | +127% |
| Equity | 10/15 | €4,310 | -€113 | -€4,423 | |
| Contributions | 10/11 | €20,000 | €20,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€15,690 | -€20,113 | -€4,423 | -28.2% |
| Amounts payable | 17/49 | - | €9,876 | +€9,876 | |
| Amounts payable within one year | 42/48 | - | €9,876 | +€9,876 | |
| Other amounts payable | 47/48 | - | €9,876 | +€9,876 | |
| Gross operating margin | 9900 | -€548 | -€4,268 | -€3,720 | -679% |
| Operating profit (loss) | 9901 | -€548 | -€4,268 | -€3,720 | -679% |
| Financial charges | 65/66B | €174 | €155 | -€19 | -10.7% |
| Recurring financial charges | 65 | €174 | €155 | -€19 | -10.7% |
| Profit (loss) for the period before taxes | 9903 | -€721 | -€4,423 | -€3,702 | -513% |
| Profit (loss) for the period | 9904 | -€721 | -€4,423 | -€3,702 | -513% |
| Profit (loss) for the period to be appropriated | 9905 | -€721 | -€4,423 | -€3,702 | -513% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 1 November 2026 via checked.be.